Sanofi (SNYNF)
| Previous close | 92.70 |
| Open | 92.70 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 92.70 - 92.70 |
| 52-week range | 86.12 - 114.90 |
| Volume | |
| Avg. volume | 44,475 |
| Market cap | 115.711B |
| Beta (5Y monthly) | 0.45 |
| PE ratio (TTM) | 20.28 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.06 (4.38%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
- Reuters
Sanofi to overhaul US operations of vaccines, cut jobs
Sanofi would implement a "streamlined strategic sales structure" to better support its customers and patients, it said without disclosing any details on the changes to be made, the timeframe and the number of employees to be impacted. Sanofi CEO Paul Hudson has been trying to build investor confidence in the company's drug pipeline since he unexpectedly abandoned 2025 margin targets last October to instead boost drug development spending. The company's vaccine portfolio includes preventive shots for a common respiratory infection in infants, influenza vaccines, COVID vaccines and vaccines for infections like meningitis and tetanus.
- Insider Monkey
10 Best Weight Loss Drug Stocks to Buy Now
In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]
- Reuters
UPDATE 2-Cyclicals drive modest gains across European stocks
The continent-wide STOXX 600 index closed up 0.2%, led by a 1.7% gain in the basic resources sector as copper prices hit their highest in more than 14 months. "Recent inflation trends in Europe stand in stark contrast to what is happening in the U.S.," as per strategists at BCA Research. "This divergence in inflationary dynamics will force the ECB to be more dovish than the Fed."
